Janssen gets expanded authorization for Genmab's Darzalex in EU

On Tuesday, the EU Commission approved Genmab's Darzalex for treating the rare disease light-chain amyloidosis.

Photo: Tuala Hjarnø / Genmab / PR

Genmab's collaborative partner Janssen has received a European marketing Authorization for Darzalex for treating the rare disease Light-chain (AL) amyloidosis.

The EU Commission has reached this decision on Tuesday after an expert panel recommended approving Darzalex in May.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs